<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01010217</url>
  </required_header>
  <id_info>
    <org_study_id>2009-0266</org_study_id>
    <secondary_id>NCI-2011-03144</secondary_id>
    <nct_id>NCT01010217</nct_id>
  </id_info>
  <brief_title>Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide</brief_title>
  <official_title>Three-arm Clinical Trial for Patients With Hematologic Malignancies and Mismatched Donors - Haploidentical, 1 Antigen Mismatch Related or Unrelated, and Matched Unrelated Donor (MUD)- Using a T-cell Replete Allograft and High-dose Post-transplant Cyclophosphamide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn about the safety of giving a stem cell
      transplant from a tissue-mismatched donor, followed by cyclophosphamide, to patients with
      certain types of blood disorders or blood cancers. Melphalan, thiotepa, and fludarabine will
      also be given before the transplant.

      Researchers will study the health status of these patients at 3 months after the transplant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Study Treatment:

      Cyclophosphamide is designed to interfere with the multiplication of cancer cells, which may
      slow or stop their growth and spread throughout the body. This may cause the cancer cells to
      die.

      In this study, researchers want to learn if cyclophosphamide can help to prevent
      graft-versus-host disease (GVHD -- when transplanted immune tissue, such as white blood
      cells, attacks the tissues of the recipient's body).

      Melphalan, thiotepa, and fludarabine are commonly used in combination with a stem cell
      transplant.

      Study Treatment Administration:

      If you are found to be eligible to take part in this study, you will receive chemotherapy for
      6 days:

        -  You will receive melphalan by vein over 30 minutes on Day -8 (8 days before the
           transplant).

        -  You will receive thiotepa by vein over 4 hours on Day -7.

        -  You will receive fludarabine by vein over 1 hour on Days -6, -5, -4, and -3.

      If thiotepa is not available, you will receive melphalan by vein over 30 minutes on Day -6
      and fludarabine by vein over 1 hour on Days -5, -4, -3, and -2. You will receive total body
      irradiation (TBI) on Day -1.

      On Day 0, you will receive the donor's stem cells by vein. This may last anywhere from 15
      minutes to several hours.

      On Days 3 and 4, you will receive cyclophosphamide by vein over 3 hours. You will also
      receive mesna by vein over 30 minutes every 4 hours for a total of 10 mesna doses on Days 3
      and 4. Mesna is given to lower the risk of side effects to the bladder.

      Starting on Day 5, you will receive tacrolimus and mycophenolate mofetil (MMF) to help lower
      the risk of GVHD. Tacrolimus will be given by vein as a continuous infusion for about 2
      weeks. After the 2 weeks of taking tacrolimus by vein, you will take tacrolimus by mouth as a
      pill for at least 3 months. MMF will be given by mouth, 3 times a day, usually until Day 35.

      Starting on Day 7, you will receive filgrastim (G-CSF) once a day as an injection under the
      skin, until your blood cell counts reach a high enough level.

      Depending on the type of disease that you have, your doctor may decide to give you rituximab
      by vein over several hours on Days -13, -6, 1, and 8. Rituximab is given to help the body get
      rid of abnormal white blood cells.

      Length of Study Participation:

      You will be in the hospital for about 4 weeks after the transplant. You will be taken off
      study if the disease gets worse. The study drugs will be stopped if intolerable side effects
      occur.

      Follow-Up Visits:

      You will be asked to stay close enough to Houston to be able to come back for any visits for
      at least 100 days after the transplant.

      At 1, 3, 6, and 12 months after the transplant, the following tests and procedures will be
      performed:

        -  You will have a physical exam.

        -  Blood (about 4 tablespoons) will be drawn for routine tests.

        -  You will have a bone marrow biopsy/aspirate to check the status of the disease. If you
           have lymphoma or aplastic anemia, you may have a bone marrow biopsy/aspirate at 3, 6,
           and 12 months, if your doctor thinks it is needed.

        -  Blood (about 4 tablespoons) will be drawn to measure tumor cells and to predict graft
           failure and/or relapse.

        -  You may have urine collected and/or scans performed such as x-rays, CT scans, and/or a
           positron emission tomography (PET) scan. These scans and urine tests would only be done
           if the study doctor thinks they are needed to check the status of the disease.

        -  Blood (about 4 tablespoons) will be drawn to check your immune system.

      If you have AML, at 2 months after the transplant, blood (about 4 tablespoons) will be drawn
      to check your immune system.

      If you have MM, you will have a bone survey once a year.

      If the study doctor thinks it is needed based on side effects you may be having, additional
      follow-up tests will be performed.

      You may be contacted by phone 1-2 times a year to ask about the status of the disease. These
      calls will take about 10 minutes to complete.

      This is an investigational study. All of the drugs used in this study are commercially
      available and FDA approved. However, it is investigational to give high-dose cyclophosphamide
      for preventing GVHD that may occur after a stem cell transplant from a tissue-mismatched
      donor.

      Up to 337 patients will take part in this study. All will be enrolled at MD Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 5, 2009</start_date>
  <completion_date type="Actual">October 5, 2017</completion_date>
  <primary_completion_date type="Actual">October 5, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Non-relapse Mortality (NRM)</measure>
    <time_frame>At 100 days</time_frame>
    <description>Non-relapse mortality (NRM) is defined as death from any cause other than relapse disease. Bayesian monitoring scheme described in Thall, Simon, and Estey (1996) employed to perform interim monitoring of the data during the course of the trial separately within each group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Non Related Mortality (NRM)</measure>
    <time_frame>six months</time_frame>
    <description>Non-relapse mortality (NRM) is defined as death from any cause other than relapse disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Engraftments</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade III-IV aGVHD</measure>
    <time_frame>100 days</time_frame>
    <description>Acute Graft vs host disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cGVHD</measure>
    <time_frame>1 year</time_frame>
    <description>Chronic graft vs host disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survival</measure>
    <time_frame>1 year</time_frame>
    <description>Participants who have survived without their original disease.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">176</enrollment>
  <condition>Blood Stem Cell Transplant Failure</condition>
  <condition>Leukemia</condition>
  <condition>Hematologic Malignancies</condition>
  <arm_group>
    <arm_group_label>Haploidentical related</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 1 - Stem Cell Transplantation (SCT), Melphalan 140 mg/m^2 , Thiotepa 5 mg/kg, Fludarabine 40 mg/m^2 + high-dose post-transplant cyclophosphamide 50 mg/kg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1 Antigen Mismatch Related or Unrelated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 2 - SCT, Melphalan, Thiotepa, Fludarabine + high-dose post-transplant cyclophosphamide.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matched Unrelated Donor (MUD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 3 - SCT, Melphalan, Thiotepa, Fludarabine + high-dose post-transplant cyclophosphamide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>50 mg/kg/day intravenous (IV) over 3 hours on Days 3 and 4.</description>
    <arm_group_label>1 Antigen Mismatch Related or Unrelated</arm_group_label>
    <arm_group_label>Haploidentical related</arm_group_label>
    <arm_group_label>Matched Unrelated Donor (MUD)</arm_group_label>
    <other_name>Cytoxan</other_name>
    <other_name>Neosar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>40 mg/m^2 IV over 1 hour on Days -6, -5, -4, and -3.</description>
    <arm_group_label>1 Antigen Mismatch Related or Unrelated</arm_group_label>
    <arm_group_label>Haploidentical related</arm_group_label>
    <arm_group_label>Matched Unrelated Donor (MUD)</arm_group_label>
    <other_name>Fludara</other_name>
    <other_name>Fludarabine Phosphate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>140 mg/m^2 IV (or 100 mg/m^2 with reduced intensity Regimen 2) over 30 minutes on Day -8.</description>
    <arm_group_label>1 Antigen Mismatch Related or Unrelated</arm_group_label>
    <arm_group_label>Haploidentical related</arm_group_label>
    <arm_group_label>Matched Unrelated Donor (MUD)</arm_group_label>
    <other_name>Alkeran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesna</intervention_name>
    <description>10 mg/kg IV every 4 hours for a total of 10 doses starting just prior to first dose of Cyclophosphamide on Days 3 and 4.</description>
    <arm_group_label>1 Antigen Mismatch Related or Unrelated</arm_group_label>
    <arm_group_label>Haploidentical related</arm_group_label>
    <arm_group_label>Matched Unrelated Donor (MUD)</arm_group_label>
    <other_name>Mesnex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>CD20+ lymphoid malignancies: 375 mg/m2 on Day -13 followed by 1000 mg/m2 on Day -6, +1, and +8.</description>
    <arm_group_label>1 Antigen Mismatch Related or Unrelated</arm_group_label>
    <arm_group_label>Haploidentical related</arm_group_label>
    <other_name>Rituxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stem Cell Transplantation</intervention_name>
    <description>Infusion of donor's stem cells by vein on Day 0, may last anywhere from 15 minutes to several hours.</description>
    <arm_group_label>1 Antigen Mismatch Related or Unrelated</arm_group_label>
    <arm_group_label>Haploidentical related</arm_group_label>
    <other_name>SCT</other_name>
    <other_name>Blood Marrow Transplantation</other_name>
    <other_name>Allogeneic stem cell transplantation</other_name>
    <other_name>ASCT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thiotepa</intervention_name>
    <description>5 mg/kg Regimen 1 (or 5 mg/kg with reduced intensity Regimen 2) IV over 4 hours on Day -7.</description>
    <arm_group_label>1 Antigen Mismatch Related or Unrelated</arm_group_label>
    <arm_group_label>Haploidentical related</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>0.015 mg/kg by vein or orally daily starting on Day +5 for 3 months</description>
    <arm_group_label>1 Antigen Mismatch Related or Unrelated</arm_group_label>
    <arm_group_label>Haploidentical related</arm_group_label>
    <arm_group_label>Matched Unrelated Donor (MUD)</arm_group_label>
    <other_name>Prograf</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycofenolate mofetil</intervention_name>
    <description>15 mg/kg/dose orally three times a day starting on Day +5 to Day +100 or otherwise indicated</description>
    <arm_group_label>1 Antigen Mismatch Related or Unrelated</arm_group_label>
    <arm_group_label>Haploidentical related</arm_group_label>
    <arm_group_label>Matched Unrelated Donor (MUD)</arm_group_label>
    <other_name>MMF</other_name>
    <other_name>CellCept</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-CSF</intervention_name>
    <description>5 mcg/kg/day subcutaneously starting Day 7 once a day daily until neutrophil recovery &gt; 1000/mcl.</description>
    <arm_group_label>1 Antigen Mismatch Related or Unrelated</arm_group_label>
    <arm_group_label>Haploidentical related</arm_group_label>
    <arm_group_label>Matched Unrelated Donor (MUD)</arm_group_label>
    <other_name>Filgrastim</other_name>
    <other_name>Neupogen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients &lt; 55 years (Myeloablative regimen #1) or &gt; 55 and &lt;/= 75 years or significant
             comorbidities (Reduced intensity regimen #2) old lacking a matched related volunteer
             donor identified in time for transplant for which a related haploidentical donor (&lt;/=
             7/8 allele match at the A, B, C, DR loci), a 7/8 allele matched related or unrelated
             donor is identified, or a matched unrelated donor (MUD). The patients must be
             diagnosed with a high-risk disease defined as following:

          2. Acute lymphocytic leukemia (ALL) in CR1 with high-risk features including adverse
             cytogenetics such as t(9;22), t(1;19), t(4;11), or MLL gene rearrangements; ALL in
             second or greater remission or ALL with relapsed disease, peripheral blood blasts &lt;
             1000/microliter, ALL patients must show response to most recent received chemotherapy;

          3. Acute myeloid leukemia (AML) in CR1 with intermediate-risk disease or high-risk
             features defined as: Greater than 1 cycle of induction therapy required to achieve
             remission; Preceding myelodysplastic syndrome (MDS) or myeloproliferative disease;
             Presence of FLT3 mutations or internal tandem duplications; FAB M6 or M7
             classification; Adverse cytogenetics, -5, del 5q, -7, del7q, abnormalities involving
             3q, 9q, 11q, 20q, 21q, 17, +8 [&gt; 3 abnormalities], peripheral blood blasts
             &lt;1000/microliter, AML patients must show response to most recent received
             chemotherapy;

          4. AML in second or greater remission, primary induction failure and patients with
             relapsed disease, peripheral blood blasts &lt;1000/microliter; patients &gt; 55 years and
             &lt;/= 75 years need to be in morphologic remission at transplant (&lt; 5% blasts).

          5. Myelodysplastic syndrome (MDS) with International Prognostic Scoring System (IPSS)
             intermediate-2 or higher; or therapy-related MDS

          6. Aplastic anemia with Absolute neutrophil count (ANC)&lt;1000 and transfusion dependent
             after they failed immunosuppression therapy

          7. Chronic myeloid leukemia (CML) &gt;/=1st chronic phase, after failed &gt;/=2 lines of
             tyrosine kinase inhibitors; in accelerated or blast phase with &gt; 30% bone marrow
             blasts;

          8. Prior allogeneic stem cell transplant more than 6 months from the first transplant, in
             remission.

          9. Chemotherapy-sensitive relapsed lymphoma (Complete or partial response), Hodgkin's or
             non-Hodgkin's lymphoma, no evidence of &quot;bulky&quot; disease (&gt; 10 cm in diameter);

         10. Patients with chemo-sensitive CLL with persistent or recurrent disease after
             fludarabine-based regimens, no evidence of &quot;bulky&quot; disease (&gt; 10 cm in diameter)

         11. Patients with poor prognosis multiple myeloma by cytogenetics (del13, del 17p, t(1;14)
             or t(14;16) or hypodiploidy, with advanced disease (stage&gt;/=2) and /or relapsed after
             autologous stem cell transplant.

         12. Patients with myelofibrosis (Lille &gt;0, transfusion dependency, progression to blast
             phase; however, in remission from AML) or chronic myelomonocytic leukemia (CMML).
             These patients will be treated with the reduced-intensity conditioning regimen #2 and
             will be subject to the same stopping rule as the group &gt;/= 55 years or with
             comorbidities.

         13. Zubrod performance status 0-1 or Lansky PS greater or equal to 70%.

         14. Patients above &gt;/=65 years old should have an age-adjusted co-morbidity index of &lt;/=
             3.

         15. Available donor able to undergo a bone marrow harvest. For matched unrelated donor
             transplants only: Peripheral blood stem cells may be collected if donor is unavailable
             for bone marrow harvest or if adequate bone marrow cannot be collected.

         16. Bilirubin &lt;/= 1.5 mg/dl (unless Gilbert's syndrome), ALT or AST &lt;/= 200 IU/ml.

         17. Serum creatinine clearance &gt;/=50 ml/min (calculated with Cockcroft-Gault formula);
             Creatinine for children &lt;/=1.5 mg/dl or &lt;/=2 times upper limit of normal for age
             (whichever is less);

         18. Diffusing capacity for carbon monoxide (DLCO) &gt;/= 45% predicted corrected for
             hemoglobin. For pediatric patients, if unable to perform pulmonary function, &gt;/= 92%
             oxygen saturation with pulse oximetry.

         19. Left ventricular ejection fraction (LVEF) &gt;/= 40%.

         20. Patient or patient's legal representative, parent(s) or guardian should provide
             written informed consent. Assent of a minor if participant's age is at least seven and
             less than eighteen years.

        Exclusion Criteria:

          1. HIV positive; active hepatitis B or C

          2. Patients with active infections. The PI is the final arbiter of the eligibility.

          3. Liver cirrhosis with greater than grade 1 stage 1 inflammation/fibrosis

          4. Uncontrolled central nervous system (CNS) involvement by tumor cells

          5. Patients with AML must have less than 30% bone marrow blasts and no peripheral blood
             blasts.

          6. History of another primary malignancy that has not been in remission for at least 3
             years. (The following are exempt from the 3-year limit: non-invasive nonmelanoma skin
             cancer, fully excised melanoma in situ [Stage 0], curatively treated localized
             prostate cancer, and cervical carcinoma in situ on biopsy or a squamous
             intraepithelial lesion on PAP smear.)

          7. Positive Beta human chorionic gonadotropin (HCG) test in a woman with child bearing
             potential defined as not post-menopausal for 12 months or no previous surgical
             sterilization.

          8. Inability to comply with medical therapy or follow-up.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Ciurea, MD</last_name>
    <role>Study Chair</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>November 6, 2009</study_first_submitted>
  <study_first_submitted_qc>November 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2009</study_first_posted>
  <results_first_submitted>May 15, 2019</results_first_submitted>
  <results_first_submitted_qc>December 19, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">January 7, 2020</results_first_posted>
  <last_update_submitted>March 12, 2020</last_update_submitted>
  <last_update_submitted_qc>March 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hematologic Neoplasms</keyword>
  <keyword>Blood Disorders</keyword>
  <keyword>Blood Cancer</keyword>
  <keyword>Transplantation, Blood And Marrow</keyword>
  <keyword>Acute myelogenous leukemia</keyword>
  <keyword>Myelodysplastic syndrome</keyword>
  <keyword>Acute lymphocytic leukemia</keyword>
  <keyword>Aplastic anemia</keyword>
  <keyword>Chronic myelogenous leukemia</keyword>
  <keyword>Chronic lymphocytic leukemia</keyword>
  <keyword>Myeloproliferative disease</keyword>
  <keyword>Hodgkin's disease</keyword>
  <keyword>Non-Hodgkin's lymphoma</keyword>
  <keyword>Multiple myeloma</keyword>
  <keyword>Cyclophosphamide</keyword>
  <keyword>Fludarabine</keyword>
  <keyword>Melphalan</keyword>
  <keyword>Mesna</keyword>
  <keyword>Rituximab</keyword>
  <keyword>Tacrolimus</keyword>
  <keyword>Prograf</keyword>
  <keyword>Mycofenolate mofetil</keyword>
  <keyword>MMF</keyword>
  <keyword>CellCept</keyword>
  <keyword>G-CSF</keyword>
  <keyword>Filgrastim</keyword>
  <keyword>Neupogen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vidarabine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 26, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/17/NCT01010217/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were enrolled during the period from January 2010 through August 2014 and were assigned to the HAPLO arm or the 9/10 MUD arm based on donor availability and physician preference. The 3 arms received identical melphalan-based conditioning chemotherapy and GVHD prophylaxis</recruitment_details>
      <pre_assignment_details>Additional arm elderly patients did not accrue any participants so therefore was excluded from summary.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Haplo Arm</title>
          <description>Patients that received a stem cell transplant from a haploidentical donor.</description>
        </group>
        <group group_id="P2">
          <title>1AgMM Related/Unrelated Donors</title>
          <description>Patients that received a transplant from a 1 antigen mismatched related or unrelated donor</description>
        </group>
        <group group_id="P3">
          <title>MUD Donor</title>
          <description>Patients that received a transplant from a matched unrelated donor</description>
        </group>
        <group group_id="P4">
          <title>Second Transplant</title>
          <description>Patients receiving a second transplant</description>
        </group>
        <group group_id="P5">
          <title>Myelofibrosis</title>
          <description>Patients with the diagnosis of Myelofibrosis</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="89"/>
                <participants group_id="P2" count="56"/>
                <participants group_id="P3" count="22"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="84"/>
                <participants group_id="P2" count="51"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Haplo Arm</title>
          <description>Patients that received a transplant from a haploindentical donor</description>
        </group>
        <group group_id="B2">
          <title>1AgMM Related/Unrelated Donors</title>
          <description>Patients that received a transplant from a 1 antigen mismatched related or unrelated donor</description>
        </group>
        <group group_id="B3">
          <title>MUD Donor</title>
          <description>Patients that received a transplant from a matched unrelated donor</description>
        </group>
        <group group_id="B4">
          <title>Second Transplant</title>
          <description>Patients receiving a second transplant</description>
        </group>
        <group group_id="B5">
          <title>Myelofibrosis</title>
          <description>Patients with the diagnosis of Myelofibrosis</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="84"/>
            <count group_id="B2" value="51"/>
            <count group_id="B3" value="21"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="3"/>
            <count group_id="B6" value="165"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="147"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="75"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="141"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="111"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patients with hematologic malignancies without a matched donor</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Non-relapse Mortality (NRM)</title>
        <description>Non-relapse mortality (NRM) is defined as death from any cause other than relapse disease. Bayesian monitoring scheme described in Thall, Simon, and Estey (1996) employed to perform interim monitoring of the data during the course of the trial separately within each group.</description>
        <time_frame>At 100 days</time_frame>
        <population>Second Transplant and Myelofibrosis was not evaluated due to low accrual.</population>
        <group_list>
          <group group_id="O1">
            <title>Haplo Arm</title>
            <description>Patients that received a transplant from a haploidentical donor</description>
          </group>
          <group group_id="O2">
            <title>1AgMM Related/Unrelated Donors</title>
            <description>Patients that received a transplant from a 1 antigen mismatched related or unrelated donor</description>
          </group>
          <group group_id="O3">
            <title>MUD Donor</title>
            <description>Patients that received a transplant from a matched unrelated donor</description>
          </group>
          <group group_id="O4">
            <title>Second Transplant</title>
            <description>Patients receiving a second transplant</description>
          </group>
          <group group_id="O5">
            <title>Myelofibrosis</title>
            <description>Patients with the diagnosis of Myelofibrosis</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Non-relapse Mortality (NRM)</title>
          <description>Non-relapse mortality (NRM) is defined as death from any cause other than relapse disease. Bayesian monitoring scheme described in Thall, Simon, and Estey (1996) employed to perform interim monitoring of the data during the course of the trial separately within each group.</description>
          <population>Second Transplant and Myelofibrosis was not evaluated due to low accrual.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Non Related Mortality (NRM)</title>
        <description>Non-relapse mortality (NRM) is defined as death from any cause other than relapse disease.</description>
        <time_frame>six months</time_frame>
        <population>Second Transplant and Myelofibrosis was not evaluated due to low accrual.</population>
        <group_list>
          <group group_id="O1">
            <title>Haplo Arm</title>
            <description>Patients that received a transplant from a haploidentical donor</description>
          </group>
          <group group_id="O2">
            <title>1AgMM Related/Unrelated Donors</title>
            <description>Patients that received a transplant from a 1 antigen mismatched related or unrelated donor</description>
          </group>
          <group group_id="O3">
            <title>MUD Donor</title>
            <description>Patients that received a transplant from a matched unrelated donor</description>
          </group>
          <group group_id="O4">
            <title>Second Transplant</title>
            <description>Patients receiving a second transplant</description>
          </group>
          <group group_id="O5">
            <title>Myelofibrosis</title>
            <description>Patients with the diagnosis of Myelofibrosis</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Non Related Mortality (NRM)</title>
          <description>Non-relapse mortality (NRM) is defined as death from any cause other than relapse disease.</description>
          <population>Second Transplant and Myelofibrosis was not evaluated due to low accrual.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Engraftments</title>
        <time_frame>Day 28</time_frame>
        <population>Second Transplant and Myelofibrosis was not evaluated due to low accrual.</population>
        <group_list>
          <group group_id="O1">
            <title>Haplo Arm</title>
            <description>Patients that received a transplant from a haploidentical donor</description>
          </group>
          <group group_id="O2">
            <title>1AgMM Related/Unrelated Donors</title>
            <description>Patients that received a transplant from a 1 antigen mismatched related or unrelated donor</description>
          </group>
          <group group_id="O3">
            <title>MUD Donor</title>
            <description>Patients that received a transplant from a matched unrelated donor</description>
          </group>
          <group group_id="O4">
            <title>Second Transplant</title>
            <description>Patients receiving a second transplant</description>
          </group>
          <group group_id="O5">
            <title>Myelofibrosis</title>
            <description>Patients with the diagnosis of Myelofibrosis</description>
          </group>
        </group_list>
        <measure>
          <title>Engraftments</title>
          <population>Second Transplant and Myelofibrosis was not evaluated due to low accrual.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="50"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Grade III-IV aGVHD</title>
        <description>Acute Graft vs host disease</description>
        <time_frame>100 days</time_frame>
        <population>Second Transplant and Myelofibrosis was not evaluated due to low accrual</population>
        <group_list>
          <group group_id="O1">
            <title>Haplo Arm</title>
            <description>Patients that received a transplant from a haploidentical donor</description>
          </group>
          <group group_id="O2">
            <title>1AgMM Related/Unrelated Donors</title>
            <description>Patients that received a transplant from a 1 antigen mismatched related or unrelated donor</description>
          </group>
          <group group_id="O3">
            <title>MUD Donor</title>
            <description>Patients that received a transplant from a matched unrelated donor</description>
          </group>
          <group group_id="O4">
            <title>Second Transplant</title>
            <description>Patients receiving a second transplant</description>
          </group>
          <group group_id="O5">
            <title>Myelofibrosis</title>
            <description>Patients with the diagnosis of Myelofibrosis</description>
          </group>
        </group_list>
        <measure>
          <title>Grade III-IV aGVHD</title>
          <description>Acute Graft vs host disease</description>
          <population>Second Transplant and Myelofibrosis was not evaluated due to low accrual</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>cGVHD</title>
        <description>Chronic graft vs host disease</description>
        <time_frame>1 year</time_frame>
        <population>Second Transplant and Myelofibrosis was not evaluated due to low accrual.</population>
        <group_list>
          <group group_id="O1">
            <title>Haplo Arm</title>
            <description>Patients that received a transplant from a haploidentical donor</description>
          </group>
          <group group_id="O2">
            <title>1AgMM Related/Unrelated Donors</title>
            <description>Patients that received a transplant from a 1 antigen mismatched related or unrelated donor</description>
          </group>
          <group group_id="O3">
            <title>MUD Donor</title>
            <description>Patients that received a transplant from a matched unrelated donor</description>
          </group>
          <group group_id="O4">
            <title>Second Transplant</title>
            <description>Patients receiving a second transplant</description>
          </group>
          <group group_id="O5">
            <title>Myelofibrosis</title>
            <description>Patients with the diagnosis of Myelofibrosis</description>
          </group>
        </group_list>
        <measure>
          <title>cGVHD</title>
          <description>Chronic graft vs host disease</description>
          <population>Second Transplant and Myelofibrosis was not evaluated due to low accrual.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Free Survival</title>
        <description>Participants who have survived without their original disease.</description>
        <time_frame>1 year</time_frame>
        <population>Second Transplant and Myelofibrosis was not evaluated due to low accrual.</population>
        <group_list>
          <group group_id="O1">
            <title>Haplo Arm</title>
            <description>Patients that received a transplant from a haploidentical donor</description>
          </group>
          <group group_id="O2">
            <title>1AgMM Related/Unrelated Donors</title>
            <description>Patients that received a transplant from a 1 antigen mismatched related or unrelated donor</description>
          </group>
          <group group_id="O3">
            <title>MUD Donor</title>
            <description>Patients that received a transplant from a matched unrelated donor</description>
          </group>
          <group group_id="O4">
            <title>Second Transplant</title>
            <description>Patients receiving a second transplant</description>
          </group>
          <group group_id="O5">
            <title>Myelofibrosis</title>
            <description>Patients with the diagnosis of Myelofibrosis</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Free Survival</title>
          <description>Participants who have survived without their original disease.</description>
          <population>Second Transplant and Myelofibrosis was not evaluated due to low accrual.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the start of the preparative regiment up to day 100.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Haplo Arm</title>
          <description>Patients that received a transplant from a haploindentical donor</description>
        </group>
        <group group_id="E2">
          <title>1AgMM Related/Unrelated Donors</title>
          <description>Patients that received a transplant from a 1 antigen mismatched related or unrelated donor</description>
        </group>
        <group group_id="E3">
          <title>MUD Donor</title>
          <description>Patients that received a transplant from a matched unrelated donor</description>
        </group>
        <group group_id="E4">
          <title>Second Transplant</title>
          <description>Patients receiving a second transplant</description>
        </group>
        <group group_id="E5">
          <title>Myelofibrosis</title>
          <description>Patients with the diagnosis of Myelofibrosis</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Graft failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic GI GVHD</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>GI GVHD</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Upper GI GVHD</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Adenocirus viremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Altered mental status</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>BK virus associated hemorrhagic cystitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ARDS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Fungal pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Pulmonary edema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="84" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune hemolytic anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Delayed Engraftment</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Elevated WBC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Graft failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Secondary graft failure</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>TMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic Ocular GVHD</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>C difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Chorioretinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Chronic GI GVHD</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>GI bleed</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>GI GVHD</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>GI pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="84" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Upper GI GVHD</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic Oral GVHD</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Metabolic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic Liver GVHD</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Elevated ALK Phosphatase</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Elevated ALT</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Elevated AST</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Elevated bilirubin</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Liver GVHD</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Veno occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>CMV chorioretinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Disseminated toxoplasmosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Idiopathic pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Viral Infection</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Neutropenic fever</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Neutropenic Typhlitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>HSV oral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Infusion reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Myopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Altered mental status</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Tremors</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute renal failure</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>BK virus associated hemorrhagic cystitis</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Hemorrhagic cystitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Renal insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>DAH</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Fungal pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Pulmonary edema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Shortness of Breath</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Chemo Burn</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Chronic Skin GVHD</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Hand/Foot syndrome</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Skin rash</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Skin GVHD</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Stefan O Ciurea, Associate Profeddor of Stem Cell Transplantation</name_or_title>
      <organization>UT MD Anderson Cancer Center</organization>
      <phone>713-745-0146</phone>
      <email>sciurea@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

